

Resource Summary Report

Generated by [dkNET](#) on Aug 27, 2026

BARD

RRID:SCR_006283

Type: Tool

Proper Citation

BARD (RRID:SCR_006283)

Resource Information

URL: <http://bard.nih.gov/>

Proper Citation: BARD (RRID:SCR_006283)

Description: Database that allows scientists without specialized training to effectively utilize Molecular Libraries Program (MLP) data. It allows the research community to utilize and develop new chemical probes to explore biological functions by building a central, permanently accessible link to all aspects of chemical biology data and analyses. The project is split into two basic segments, the first segment delivering functionality for a data dictionary, as well as assay protocol and data entry tools. The second builds a data warehouse for analysis and visualization, accessible through a public RESTful API. They will initially deploy two clients that will use this API - a web-based interface and a desktop application. Advanced access to data and the platforms will also be available to support plug-in development and the repackaging of data by others. Initially the project will focus on small molecule assays. Features: * allow scientists to annotate assay data using a common, shared language * provide facile access to data, integrating existing chemical biology and computational resources * enable meaningful analysis and interpretation of discovery data by the research community * support hypothesis generation for iterative probe- and drug-discovery projects * inform the entire small molecule discovery and development process, THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Abbreviations: BARD

Synonyms: BioAssay Research Database, BioAssay Research Database (BARD)

Resource Type: data or information resource, database

Keywords: chemical biology, chemical probe, small molecule, drug discovery, data set, FASEB list

Funding: NIH

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: BARD

Resource ID: SCR_006283

Alternate IDs: nlx_151903

Record Creation Time: 20220129T080235+0000

Record Last Update: 20260821T193745+0000

Ratings and Alerts

No rating or validation information has been found for BARD.

No alerts have been found for BARD.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 135 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mulet-Perreault H, et al. (2025) Mini-SEA: Validity and Normative Data for the French-Quebec Population Aged 50??Years and Above. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, 40(3), 694.

Thompson LE, et al. (2025) Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin. AAPS open, 11.

Zhao Y, et al. (2025) BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization. Clinical trials (London, England), 22(4), 393.

Omar T, et al. (2025) Causes of death in adults living with HIV in South Africa: A single-centre postmortem study. Southern African journal of HIV medicine, 26(1), 1673.

Dallio M, et al. (2025) FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). International journal of molecular sciences, 26(2).

Li J, et al. (2025) The essential oil from the rhizomes of Stahlianthus involucratus attenuates the progression of vascular aging and atherosclerosis by regulating Nrf2-mediated mitochondrial quality. Frontiers in pharmacology, 16, 1579333.

Georgiopoulos G, et al. (2025) Incremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification. *The Journal of clinical endocrinology and metabolism*, 110(4), 1115.

Mitman SL, et al. (2025) Pharmacokinetics of Orally Administered Phenazopyridine in Goats With Obstructive Urolithiasis. *Journal of veterinary internal medicine*, 39(4), e70167.

Luo G, et al. (2025) Retrospective Study on Ureteroscopic Lithotripsy in Patients with Ureteral Duplication: Clinical Characteristics and Treatment Outcomes. *Research and reports in urology*, 17, 271.

Dentella V, et al. (2025) Language in vivo vs. in silico: Size matters but Larger Language Models still do not comprehend language on a par with humans due to impenetrable semantic reference. *PloS one*, 20(7), e0327794.

Rahimli Ocakoglu S, et al. (2024) The Emerging Role of AI in Patient Education: A Comparative Analysis of LLM Accuracy for Pelvic Organ Prolapse. *Medical principles and practice : international journal of the Kuwait University, Health Science Centre*, 33(4), 330.

Chen Y, et al. (2024) A non-invasive diagnostic nomogram for CHB-related early cirrhosis: a prospective study. *Scientific reports*, 14(1), 15343.

Cho EJ, et al. (2024) Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups. *Cardiovascular diabetology*, 23(1), 340.

Li FF, et al. (2024) Analysis of hemorrhage upon ultrasound-guided percutaneous renal biopsy in China: a retrospective study. *International urology and nephrology*, 56(5), 1713.

Asif M, et al. (2024) Correlation Between Transient Elastography and Non-invasive Biomarker Scores for the Detection of Liver Fibrosis. *Cureus*, 16(11), e72892.

Jin S, et al. (2024) Surgical treatment of graft infection combined with aortoesophageal fistula after TEVAR: a retrospective single-center, single-arm study. *Journal of cardiothoracic surgery*, 19(1), 535.

Tulone A, et al. (2024) Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease? *United European gastroenterology journal*, 12(5), 638.

Hadar-Shoval D, et al. (2024) Embedded values-like shape ethical reasoning of large language models on primary care ethical dilemmas. *Heliyon*, 10(18), e38056.

Xiang W, et al. (2024) DII modulates the relationship between SVD3 and NAFLD prevalence, rather than liver fibrosis severity, in hospitalized T2DM population. *Scientific reports*, 14(1), 25567.

Asanuma K, et al. (2024) Complications of chest wall around malignant tumors: differences based on reconstruction strategy. *BMC cancer*, 24(1), 964.